華熙生物趙燕:將準備充足資源與天貓共塑品牌,成爲國貨增長樣板
“華熙生物有充分的意願、充足的資源與天貓在全平臺共塑品牌,通過天貓成爲新一代中國品牌增長的樣板。”2025年天貓TopTalk大會上,華熙生物董事長趙燕對媒體表示,華熙生物對天貓的新戰略充滿信心,2025年華熙生物將持續加大產品研發投入,以及在天貓的投入。據悉,爲了和天貓更緊密地合作,華熙生物將組建一支年輕化團隊,專門對接天貓,雙方將深挖生命科學、美妝等領域,加大在內容端、新品端的共創,發揮雙方優勢,打造屬於中國品牌的大IP。華熙生物集團一直與淘天緊密合作。2025年開年,天貓美妝行業推出商家返傭激勵政策,華熙生物將此作爲集團發展的重要拐點,旗下所有品牌均第一時間參與。同時,在新品激勵政策下,誇迪懸油次拋2.0在天貓小黑盒開新首發,全店目標超額達成,同比增長超150%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.